Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular Features

Walid Macaron, Elias Jabbour, Nitin Jain, Fadi G. Haddad, Jayastu Senapati, Partow Kebriaei, Eitan Kugler, Kelly S. Chien, Ghayas C. Issa, Jairo Matthews, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian, Nicholas J. Short

Blood (2024) 144 (Supplement 1): 727.

https://doi.org/10.1182/blood-2024-203929

Published: 2024

Journal Articles

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Blood (2024) 144 (Supplement 1): 4263.

https://doi.org/10.1182/blood-2024-204296

Published: 2024

Journal Articles

IFNγ Signaling in Acute Myeloid Leukemia Mediates Immunomodulation and Reveals Therapeutic Strategies

Blood (2023) 142 (Supplement 1): 2796.

https://doi.org/10.1182/blood-2023-175010

Published: 2023

Journal Articles

Single-Cell Polyfunctional Proteomic Profiling Reveals Temporal and Niche Differences in CD4 and CD8 T Cells in Acute Myeloid Leukemia Following PD-1 Blockade Therapy

Jessica Lynn Root, Poonam N Desai, Patrick K Reville, Christopher Ly, Bofei Wang, Fatima Z Jelloul, Jing Zhou, Sean Gregory Mackay, Mansour Alfayez, Jairo Matthews, Sherry Pierce, Naval Daver, Hussein A Abbas

Blood (2023) 142 (Supplement 1): 1584.

https://doi.org/10.1182/blood-2023-188268

Published: 2023

Journal Articles

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Blood (2023) 142 (Supplement 1): 158.

https://doi.org/10.1182/blood-2023-186699

Published: 2023

Journal Articles

Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia

Blood (2021) 138 (18): 1733–1739.

https://doi.org/10.1182/blood.2020010483

Published: 2021

Includes: Supplemental data

Journal Articles

Sequencing of Circulating Cell-Free DNA in Patients with AML Detects Clinically Significant Mutations Not Detected in Bone Marrow: The Role for Complementary Peripheral Blood and Bone Marrow Genomic Analysis

Nicholas J. Short, MD, Keyur Patel, MD PhD, Maher Albitar, MD, Miguel Franquiz, Rashmi Kanagal-Shamanna, MD, Feng Wang, PhD, Rita Assi, MD, Guillermo Montalban-Bravo, MD, Jairo Matthews, Wanlong Ma, Ghayas C. Issa, MD, Steven M. Kornblau, MD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Zeev E. Estrov, MD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 2592.

https://doi.org/10.1182/blood-2019-125122

Published: 2019

Journal Articles

Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML)

Tomoyuki Tanaka, Kiyomi Morita, MD, Feng Wang, PhD, Latasha Little, Curtis Gumbs, Jairo Matthews, Courtney D. DiNardo, MDMSc, Tapan M. Kadia, MD, Farhad Ravandi, MD, Marina Y Konopleva, MD PhD, Hagop M. Kantarjian, MD, Richard E. Champlin, MD, Guillermo Garcia-Manero, MD, P Andrew Futreal, PhD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 17.

https://doi.org/10.1182/blood-2019-122274

Published: 2019

Journal Articles

Single-Cell Deconvolution Identifies T-Cell Correlates of Response to PD-1 Blockade Treatment in AML

Xingyue An, Jay R Adolacion, Mansour Alfayez, MD, Jairo Matthews, Wilmer Flores, Steven M. Kornblau, MD, Arash Saeedi, Sreyashi Basu, PhD, Naval G. Daver, MD, Navin Varadarajan, PhD

Blood (2019) 134 (Supplement_1): 1950.

https://doi.org/10.1182/blood-2019-122081

Published: 2019

Journal Articles

Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML

Shelley Herbrich, MS, Antonio Cavazos, Cora Marie C Cheung, BSN, Lynette Alexander-Williams, Nicholas J. Short, MD, Jairo Matthews, Naval G. Daver, MD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 1428.

https://doi.org/10.1182/blood-2019-128601

Published: 2019

Journal Articles

Comprehensive Genomic Analysis of IDH Inhibitor-Treated AML Samples Delineates Molecular Mechanisms of Differentiation and Heterogeneous Patterns of Acquired Resistance

Blood (2018) 132 (Supplement 1): 441.

https://doi.org/10.1182/blood-2018-99-116383

Published: 2018

Journal Articles

Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML)

Blood (2018) 132 (Supplement 1): 88.

https://doi.org/10.1182/blood-2018-99-117358

Published: 2018

Journal Articles

Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study

Blood (2018) 132 (Supplement 1): 906.

https://doi.org/10.1182/blood-2018-99-120157

Published: 2018

Journal Articles

Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AML

Blood (2017) 130 (Supplement 1): 1345.

https://doi.org/10.1182/blood.V130.Suppl_1.1345.1345

Published: 2017

Journal Articles

High-Throughput Single-Cell DNA Sequencing of AML Tumors with Droplet Microfluidics

Dennis J. Eastburn, PhD, Maurizio Pellegrino, PhD, Adam Sciambi, PhD, Sebastian Treusch, PhD, Kaustubh Gokhale, PhD, Jose Jacob, MS, Tina Chen, MS, Jairo Matthews, BA, Kiyomi Morita, MD, Keith Jones, PhD, Koichi Takahashi, MD

Blood (2017) 130 (Supplement 1): 3965.

https://doi.org/10.1182/blood.V130.Suppl_1.3965.3965

Published: 2017

Journal Articles

Eltrombopag for the Management of Thrombocytopenia Associated with Tyrosine Kinase Therapy in Patients with Chronic Myeloid Leukemia and Myelofibrosis

Abdallah Abou Zahr, Jorge E. Cortes, MD, Srdan Verstovsek, MD PhD, Jairo Matthews, Nitin Jain, MD, Elias J. Jabbour, MD, Guillermo Garcia-Manero, MD, Michael Andreef, MD PhD, Kiran Naqvi, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD

Blood (2016) 128 (22): 3062.

https://doi.org/10.1182/blood.V128.22.3062.3062

Published: 2016

Journal Articles

Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2016) 128 (22): 2012.

https://doi.org/10.1182/blood.V128.22.2012.2012

Published: 2016

Journal Articles

Tissue Sample Collection, Processing, Storage, Archiving and Usage in the Leukemia Tissue Bank: an M. D. Anderson Experience

Jairo Matthews, Sarah Gwen Pelletier, BS, Katie Gaw, Kavita Chauhan, Wilmer Flores, Manasi Chauhan, Giang Hoang, Elizabeth Graver, Jahn Laurel, Deanna Alexander, Sherry Pierce, BSN, BA, Steven M. Kornblau, MD

Blood (2016) 128 (22): 5168.

https://doi.org/10.1182/blood.V128.22.5168.5168

Published: 2016

Journal Articles

Analysis Of EphA3 Expression In Hematologic Malignancies By Quantitative PCR

John Woronicz, PhD, Jorge E. Cortes, MD, Jeffrey L. Jorgensen, MD, PhD, Hagop M Kantarjian, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Pramoda Challagundla, Jairo Matthews, Jennifer Ho, Jackie M. Walling, MBChB, PhD, Geoffrey Yarranton, PhD, Naveen Pemmaraju, MD

Blood (2013) 122 (21): 4981.

https://doi.org/10.1182/blood.V122.21.4981.4981

Published: 2013

Journal Articles

Eltrombopag For The Management Of Thrombocytopenia Associated With Tyrosine Kinase Therapy In Patients With Chronic Myeloid Leukemia and Myelofibrosis

Gautam Borthakur, MD, Srdan Verstovsek, MD, PhD, Elias Jabbour, MD, Jairo Matthews, Tapan M. Kadia, MD, Naval Daver, MD, Hagop M. Kantarjian, MD, Jorge Cortes, MD

Blood (2013) 122 (21): 4022.

https://doi.org/10.1182/blood.V122.21.4022.4022

Published: 2013

NARROW

Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular Features

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

IFNγ Signaling in Acute Myeloid Leukemia Mediates Immunomodulation and Reveals Therapeutic Strategies

Single-Cell Polyfunctional Proteomic Profiling Reveals Temporal and Niche Differences in CD4 and CD8 T Cells in Acute Myeloid Leukemia Following PD-1 Blockade Therapy

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia

Sequencing of Circulating Cell-Free DNA in Patients with AML Detects Clinically Significant Mutations Not Detected in Bone Marrow: The Role for Complementary Peripheral Blood and Bone Marrow Genomic Analysis

Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML)

Single-Cell Deconvolution Identifies T-Cell Correlates of Response to PD-1 Blockade Treatment in AML

Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML

Comprehensive Genomic Analysis of IDH Inhibitor-Treated AML Samples Delineates Molecular Mechanisms of Differentiation and Heterogeneous Patterns of Acquired Resistance

Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML)

Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study

Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AML

High-Throughput Single-Cell DNA Sequencing of AML Tumors with Droplet Microfluidics

Eltrombopag for the Management of Thrombocytopenia Associated with Tyrosine Kinase Therapy in Patients with Chronic Myeloid Leukemia and Myelofibrosis

Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL)

Tissue Sample Collection, Processing, Storage, Archiving and Usage in the Leukemia Tissue Bank: an M. D. Anderson Experience

Analysis Of EphA3 Expression In Hematologic Malignancies By Quantitative PCR

Eltrombopag For The Management Of Thrombocytopenia Associated With Tyrosine Kinase Therapy In Patients With Chronic Myeloid Leukemia and Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only